• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
The hematopoietic stem cell transplantation comorbidity index is of prognostic relevance for patients with myelodysplastic syndrome.造血干细胞移植合并症指数对骨髓增生异常综合征患者具有预后相关性。
Haematologica. 2009 May;94(5):729-32. doi: 10.3324/haematol.2008.002063. Epub 2009 Mar 31.
2
Clinical relevance of extra-hematologic comorbidity in the management of patients with myelodysplastic syndrome.血液系统外合并症在骨髓增生异常综合征患者管理中的临床相关性。
Haematologica. 2009 May;94(5):602-6. doi: 10.3324/haematol.2009.005702.
3
Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome.基于疾病状态和骨髓增生异常综合征患者的血液外合并症的风险分层。
Haematologica. 2011 Mar;96(3):441-9. doi: 10.3324/haematol.2010.033506. Epub 2010 Dec 6.
4
Comorbidities and FLT3-ITD abnormalities as independent prognostic indicators of survival in elderly acute myeloid leukaemia patients.合并症和FLT3-ITD异常作为老年急性髓系白血病患者生存的独立预后指标。
Hematol Oncol. 2009 Sep;27(3):148-53. doi: 10.1002/hon.889.
5
Evaluation of comorbidities at diagnosis predicts outcome in myelodysplastic syndrome patients.诊断时合并症的评估可预测骨髓增生异常综合征患者的预后。
Leuk Res. 2011 Feb;35(2):159-62. doi: 10.1016/j.leukres.2010.06.005. Epub 2010 Jul 1.
6
Association of comorbidities with overall survival in myelodysplastic syndrome: development of a prognostic model.合并症与骨髓增生异常综合征患者总生存的相关性：预后模型的建立。
J Clin Oncol. 2011 Jun 1;29(16):2240-6. doi: 10.1200/JCO.2010.31.3353. Epub 2011 May 2.
7
Combination of Frailty Status and Comorbidity Score Improves the Stratification of Survival in Patients With Myelodysplastic Syndrome Owing to Good Predictive Capability for Infection-related Mortality.脆弱状况和合并症评分的联合可改善骨髓增生异常综合征患者的生存分层，因为其对感染相关死亡率具有良好的预测能力。
Clin Lymphoma Myeloma Leuk. 2019 Dec;19(12):799-805. doi: 10.1016/j.clml.2019.09.610. Epub 2019 Sep 28.
8
Improved risk stratification by the integration of the revised international prognostic scoring system with the myelodysplastic syndromes comorbidity index.改良的国际预后评分系统与骨髓增生异常综合征合并症指数的整合提高了风险分层。
Eur J Cancer. 2014 Dec;50(18):3198-205. doi: 10.1016/j.ejca.2014.09.016. Epub 2014 Oct 28.
9
Allogeneic hematopoietic cell transplantation for myelodysplastic syndrome: prognostic significance of pre-transplant IPSS score and comorbidity.异基因造血细胞移植治疗骨髓增生异常综合征：移植前 IPSS 评分和合并症的预后意义。
Bone Marrow Transplant. 2010 Mar;45(3):450-7. doi: 10.1038/bmt.2009.190. Epub 2009 Aug 10.
10
Predictive factors for the outcome of allogeneic transplantation in patients with MDS stratified according to the revised IPSS-R.根据修订后的 IPSS-R 对 MDS 患者进行分层，预测异基因移植结局的因素。
Blood. 2014 Apr 10;123(15):2333-42. doi: 10.1182/blood-2013-12-542720. Epub 2014 Feb 20.

引用本文的文献

1
MDS patient registries - achievements and challenges.骨髓增生异常综合征患者登记处——成就与挑战。
Ann Hematol. 2024 Dec;103(12):4913-4930. doi: 10.1007/s00277-024-05925-3. Epub 2024 Aug 23.
2
Assessing the Prognosis of Patients with Myelodysplastic Syndromes (MDS).评估骨髓增生异常综合征（MDS）患者的预后
Cancers (Basel). 2022 Apr 12;14(8):1941. doi: 10.3390/cancers14081941.
3
Impact of gene variants on iron overload, overall survival and leukemia-free survival in myelodysplastic syndromes.基因变异对骨髓增生异常综合征中铁过载、总生存期和无白血病生存期的影响。
Am J Cancer Res. 2021 Mar 1;11(3):955-967. eCollection 2021.
4
The Hematopoietic Cell Transplant Comorbidity Index predicts survival after allogeneic transplant for nonmalignant diseases.造血干细胞移植合并症指数预测非恶性疾病异基因移植后的生存。
Blood. 2019 Feb 14;133(7):754-762. doi: 10.1182/blood-2018-09-876284. Epub 2018 Dec 13.
5
Dynamic prognostic value of the revised international prognostic scoring system following pretransplant hypomethylating treatment in myelodysplastic syndrome.骨髓增生异常综合征患者移植前接受低甲基化治疗后，修订的国际预后评分系统的动态预后价值
Bone Marrow Transplant. 2017 Apr;52(4):522-531. doi: 10.1038/bmt.2016.295. Epub 2016 Nov 28.
6
Myelodysplastic Syndromes in the Elderly: Treatment Options and Personalized Management.老年骨髓增生异常综合征：治疗选择与个体化管理
Drugs Aging. 2015 Nov;32(11):891-905. doi: 10.1007/s40266-015-0312-7.
7
Prospective Validation of the Predictive Power of the Hematopoietic Cell Transplantation Comorbidity Index: A Center for International Blood and Marrow Transplant Research Study.造血细胞移植合并症指数预测能力的前瞻性验证：一项国际血液和骨髓移植研究中心的研究
Biol Blood Marrow Transplant. 2015 Aug;21(8):1479-87. doi: 10.1016/j.bbmt.2015.04.004. Epub 2015 Apr 7.
8
Some aspects of allogeneic stem cell transplantation in patients with myelodysplastic syndrome: advances and controversy.骨髓增生异常综合征患者异基因干细胞移植的某些方面：进展与争议
Stem Cells Cloning. 2014 Dec 4;7:101-8. doi: 10.2147/SCCAA.S50514. eCollection 2014.
9
10th anniversary of the Austrian MDS Platform: aims and ongoing projects.奥地利骨髓增生异常综合征平台成立十周年：目标与正在进行的项目
Wien Klin Wochenschr. 2015 Jan;127(1-2):12-5. doi: 10.1007/s00508-014-0627-0. Epub 2014 Nov 25.
10
Complete resolution of steroid-resistant organizing pneumonia associated with myelodysplastic syndrome following allogeneic hematopoietic cell transplantation.异基因造血细胞移植后，与骨髓增生异常综合征相关的类固醇抵抗性机化性肺炎完全缓解。
Springerplus. 2014 Jan 2;3:3. doi: 10.1186/2193-1801-3-3. eCollection 2014.

本文引用的文献

1
THE PRE-THERAPEUTIC CLASSIFICATION OF CO-MORBIDITY IN CHRONIC DISEASE.慢性病共病的治疗前分类
J Chronic Dis. 1970 Dec;23(7):455-68. doi: 10.1016/0021-9681(70)90054-8.
2
Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation.接受异基因造血细胞移植的急性髓系白血病或骨髓增生异常综合征患者基于合并症和疾病状态的结局风险分层
J Clin Oncol. 2007 Sep 20;25(27):4246-54. doi: 10.1200/JCO.2006.09.7865. Epub 2007 Aug 27.
3
Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT.造血细胞移植（HCT）特异性合并症指数：一种用于异基因造血细胞移植前风险评估的新工具。
Blood. 2005 Oct 15;106(8):2912-9. doi: 10.1182/blood-2005-05-2004. Epub 2005 Jun 30.
4
[Does Charlson-comorbidity index correlate with short-term outcome in patients with gastric cancer?].[查尔森合并症指数与胃癌患者的短期预后相关吗？]
Zentralbl Chir. 2003 Nov;128(11):970-6. doi: 10.1055/s-2003-44805.
5
Measurement and impact of comorbidity in older cancer patients.
Crit Rev Oncol Hematol. 2000 Sep;35(3):181-200. doi: 10.1016/s1040-8428(00)00090-1.
6
The impact of comorbidity and age on survival with laryngeal cancer.合并症和年龄对喉癌患者生存率的影响。
Ear Nose Throat J. 1999 Aug;78(8):578, 581-4.
7
Validation of the Charlson comorbidity index in patients with head and neck cancer: a multi-institutional study.头颈部癌患者中Charlson合并症指数的验证：一项多机构研究。
Laryngoscope. 1997 Nov;107(11 Pt 1):1469-75. doi: 10.1097/00005537-199711000-00009.
8
International scoring system for evaluating prognosis in myelodysplastic syndromes.评估骨髓增生异常综合征预后的国际评分系统。
Blood. 1997 Mar 15;89(6):2079-88.
9
Validation of a combined comorbidity index.一种合并症综合指数的验证
J Clin Epidemiol. 1994 Nov;47(11):1245-51. doi: 10.1016/0895-4356(94)90129-5.
10
A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.纵向研究中预后合并症分类的一种新方法：开发与验证
J Chronic Dis. 1987;40(5):373-83. doi: 10.1016/0021-9681(87)90171-8.

造血干细胞移植合并症指数对骨髓增生异常综合征患者具有预后相关性。

The hematopoietic stem cell transplantation comorbidity index is of prognostic relevance for patients with myelodysplastic syndrome.

作者信息

Zipperer Esther, Pelz Daniela, Nachtkamp Kathrin, Kuendgen Andrea, Strupp Corinna, Gattermann Norbert, Haas Rainer, Germing Ulrich

机构信息

Department of Haematology, Oncology and Clinical Immunology Heinrich-Heine-University, Moorenstrasse 5, Düsseldorf, Germany.

出版信息

Haematologica. 2009 May;94(5):729-32. doi: 10.3324/haematol.2008.002063. Epub 2009 Mar 31.

DOI:10.3324/haematol.2008.002063
PMID:19336740
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2675687/
Abstract

We studied the impact of comorbidities on survival and evaluated the prognostic utility of comorbidity scores in MDS patients, who received best supportive care and were assessable according to the Charlson Comorbidity Index (CCI) and the Hematopoietic Stem Cell Transplantation Comorbidity Index (HCTCI): 171 patients were identified in the Duesseldorf MDS Registry. The HCTCI captured more comorbidities. Both scoring systems had prognostic relevance, but the HCTCI more clearly distinguished between low-, intermediate- and high-risk patients. Median survival times of the different risk groups according to the HCTCI were 68, 34 and 25 months, respectively. The HCTCI showed prognostic impact in the IPSS intermediate- and high-risk group. On multivariate regression analysis, only the HCTCI remained a prognostic factor independent of IPSS. Considering their prognostic impact, comorbidities of MDS patients should receive appropriate attention in clinical trials as well as day-to-day clinical decision making.

摘要

我们研究了合并症对生存的影响，并评估了合并症评分在接受最佳支持治疗且可根据查尔森合并症指数（CCI）和造血干细胞移植合并症指数（HCTCI）进行评估的骨髓增生异常综合征（MDS）患者中的预后效用：在杜塞尔多夫MDS登记处识别出171例患者。HCTCI涵盖了更多的合并症。两种评分系统均具有预后相关性，但HCTCI能更清晰地区分低、中、高危患者。根据HCTCI划分的不同风险组的中位生存时间分别为68个月、34个月和25个月。HCTCI在国际预后评分系统（IPSS）中危和高危组显示出预后影响。在多变量回归分析中，只有HCTCI仍然是独立于IPSS的预后因素。考虑到其预后影响，MDS患者的合并症在临床试验以及日常临床决策中都应得到适当关注。